2 Blockbuster Drugs See Sudden Safety Issues

Big biotechs have gone on a huge run lately. The strength of that run largely emanates from the strength of their pipelines. Blockbuster drugs either just hitting the market or not far from a commercial debut have caused earnings projections to skyrocket, making expensive stocks look cheap in out years.

However, safety issues are a sure fire way to deny these drugs their seemingly pre-ordained profits. And to that end, two of the bigger drugs -- Celgene's Revlimid and Biogen's Tecfidera -- were recently hit with negative safety headlines.

In this video, health care analyst David Williamson discusses whether investors in Celgene and Biogen should be concerned about these sudden safety issues.

Rising health care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.

Follow David on Twitter: @MotleyDavid.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2570113, ~/Articles/ArticleHandler.aspx, 4/16/2014 1:32:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement